candlestickninja

CRBP $40 TARGET HIT, IS THE 1.618 $60 EXTENSION NEXT?

BATS:CRBP   Corbus Pharmaceuticals Holdings, Inc.
In this update, we delve into the latest developments with Corbus Pharmaceuticals (CRBP), examining whether the recent hit of our $40 target will lead to a correction to $32-$33 or propel the stock directly towards the $50s. With the 1.618 extension potentially setting a target at $59, we analyze the possibilities and implications for traders and investors.





Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.